{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:39:34Z","timestamp":1792802374494,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medicines to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and expertise to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs. Billions of tablets, capsules, intravenous and oral solutions have been donated, along with the manufacturing, supply chains and research necessary to support these efforts. Industry engagement has stimulated other donors to support NTDs with funds and oversight so that the \u2018heath benefit\u2019 return on investment in these programmes is truly a \u2018best value in public health\u2019. Many current donations are \u2018open-ended\u2019, promising support as long as necessary to achieve defined health targets. Extraordinary global health advances have been made in filariasis, onchocerciasis, trachoma, trypanosomiasis, leishmaniasis, schistosomiasis, intestinal parasites and others; and these advances are taking place in the context of strengthening health systems and meeting the global development goals espoused by the WHO. The pharmaceutical manufacturers, already strong collaborators in initiating or supporting these disease-targeted programmes, have committed to continuing their partnership roles in striving to meet the targets of the WHO's new NTD roadmap to 2030.<\/jats:p>","DOI":"10.1093\/trstmh\/traa167","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T06:09:37Z","timestamp":1607753377000},"page":"136-144","source":"Crossref","is-referenced-by-count":37,"title":["Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases"],"prefix":"10.1093","volume":"115","author":[{"given":"Mark","family":"Bradley","sequence":"first","affiliation":[{"name":"Global Health, GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Taylor","sequence":"additional","affiliation":[{"name":"Corporate Responsibility, Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Bridges to Development, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Guex","sequence":"additional","affiliation":[{"name":"International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Adrian Hopkins Consulting, Gravesend, Kent, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jensen","sequence":"additional","affiliation":[{"name":"Global Health & Patient Access, Pfizer, Inc. New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Leonard","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Global Public Health, New Brunswick, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Waltz","sequence":"additional","affiliation":[{"name":"Global Health, Group Corporate Affairs Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Kuykens","sequence":"additional","affiliation":[{"name":"Global Health Programs, Sanofi, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa Salif","family":"Sow","sequence":"additional","affiliation":[{"name":"Global Patient Solutions Africa, Gilead Sciences, Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich-Dietmar","family":"Madeja","sequence":"additional","affiliation":[{"name":"Neglected Tropical Disease Programs, Bayer AG Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hida","sequence":"additional","affiliation":[{"name":"Sustainability, Eisai Co. Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kileken","family":"Ole-Moiyoi","sequence":"additional","affiliation":[{"name":"Novartis Global Health & Corporate Responsibility, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"King","sequence":"additional","affiliation":[{"name":"Department of Control of Neglected Tropical Diseases, WHO Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Argaw","sequence":"additional","affiliation":[{"name":"Department of Control of Neglected Tropical Diseases, WHO Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamsheed","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Communicable Diseases WHO Regional Office for South-East Asia, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rebollo","family":"Polo","sequence":"additional","affiliation":[{"name":"Expanded Special Project for Elimination of NTDs (ESPEN) WHO Regional Office for Africa, Brazzaville, Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Programs for Disease Control WHO Regional Office for the Western Pacific, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ottesen","sequence":"additional","affiliation":[{"name":"NTD Support Centre, Task Force for Global Health Atlanta, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"key":"2021031805593034200_bib1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra064142","article-title":"Control of neglected tropical diseases","volume":"357","author":"Hotez","year":"2007","journal-title":"New Eng J Med"},{"key":"2021031805593034200_bib2","first-page":"399","article-title":"Mectizan donation and the Mectizan Expert Committee","volume":"59","author":"Dull","year":"1980","journal-title":"Acta Leiden"},{"key":"2021031805593034200_bib3","volume-title":"Ending the Neglect & Reaching 2020 Goals","author":"Uniting to Combat Neglected Tropical Diseases"},{"key":"2021031805593034200_bib4","doi-asserted-by":"crossref","DOI":"10.1596\/978-1-4648-0524-0_ch17","article-title":"An investment case for ending neglected tropical diseases","author":"Fitzpatrick","year":"2017"},{"issue":"5","key":"2021031805593034200_bib5","first-page":"958","article-title":"The Elimination of Neglected Tropical Diseases (NTDs): A case study exemplifying how foreign assistance funding can be catalytic in reducing the burden of major global health conditions","volume":"70","author":"Wainwright","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021031805593034200_bib6","first-page":"728","article-title":"Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis","volume":"64","author":"Turner","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2021031805593034200_bib7","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1371\/journal.pntd.0000317","article-title":"The global programme to eliminate lymphatic filariasis: health impact after 8 years","volume":"2","author":"Ottesen","year":"2008","journal-title":"PLOS Negl Trop Dis"},{"issue":"5","key":"2021031805593034200_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008261","article-title":"Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018","volume":"14","author":"Franco","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021031805593034200_bib9","volume-title":"Weekly Epidemiological Record (Lymphatic Filariasis)","author":"World Health Organization"},{"key":"2021031805593034200_bib10","volume-title":"Weekly Epidemiological Record (STH and Schistosomiasis)","author":"World Health Organization"},{"key":"2021031805593034200_bib11","volume-title":"Weekly Epidemiological Record (Leishmaniasis)","author":"World Health Organization"},{"key":"2021031805593034200_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-3156.2008.02049.x","article-title":"Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis","volume":"13","author":"Thylefors","year":"2000","journal-title":"Trop Med Int Health"},{"issue":"6","key":"2021031805593034200_bib13","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1377\/hlthaff.28.6.1745","article-title":"Progress in public-private partnerships to fight neglected diseases","volume":"28","author":"Gustavsen","year":"2009","journal-title":"Health Aff"},{"issue":"supp. 1","key":"2021031805593034200_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/000349809X12502035776478","article-title":"GlaxoSmithKline and Merck & Co, Inc.: Private-sector collaboration for the elimination of lymphatic filariasis","volume":"103","author":"Gustavsen","year":"2009","journal-title":"Ann Trop Med Parasit"},{"key":"2021031805593034200_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1756-3305-7-363","article-title":"Multidimensional complexities of filariasis control in an era of large-scale mass drug administration programmes: a can of worms","volume":"7","author":"Molyneux","year":"2014","journal-title":"Parasit Vectors"},{"issue":"11","key":"2021031805593034200_bib16","doi-asserted-by":"crossref","first-page":"e0008818","DOI":"10.1371\/journal.pntd.0008818","article-title":"The NTD Supply Chain Forum \u2013 Strengthening the backbone of NTD programs globally","volume":"14","author":"Souza","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2021031805593034200_bib17","first-page":"S39","volume-title":"The role of medicine donations in the global programme for the elimination of lymphatic filariasis","author":"Williams","year":"2021"},{"key":"2021031805593034200_bib18","volume-title":"Collaborating to end Neglected Tropical Diseases: Catalysing innovation and partnerships","author":"IFPMA","year":"2020"},{"key":"2021031805593034200_bib19","volume-title":"Fexinidazole for T.B. gambiense: First new chemical entity developed by DNDi and its first all-oral cure for all stages of sleeping sickness","author":"DNDi"},{"key":"2021031805593034200_bib20","volume-title":"Creating Synergies to Beat Neglected Diseases (2020) Life Science Leader","author":"Cueni"},{"issue":"5","key":"2021031805593034200_bib21","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.clinthera.2016.02.031","article-title":"Progress report on Neglected Tropical Disease drug donation programs","volume":"38","author":"Cohen","year":"2016","journal-title":"Clin Ther"},{"key":"2021031805593034200_bib22","volume-title":"NTD 2030 Roadmap","author":"World Health Organisation","year":"2020."},{"key":"2021031805593034200_bib23","volume-title":"Fighting Neglected Tropical Diseases: Sanofi and WHO Partnership","author":"IFPMA","year":"2020."},{"key":"2021031805593034200_bib24","volume-title":"Reaching a Billion","author":"Uniting to Combat NTDs","year":"2020."},{"key":"2021031805593034200_bib25","volume-title":"Universal health coverage","author":"General Assembly of the United Nations","year":"2019."},{"key":"2021031805593034200_bib26","first-page":"349","volume-title":"Weekly Epidemiological Record (Trachoma).","author":"World Health Organization","year":"2020"},{"key":"2021031805593034200_bib27","first-page":"513","volume-title":"Weekly Epidemiological Record (Onchocerciasis)","author":"World Health Organization","year":"2019"},{"issue":"9","key":"2021031805593034200_bib28","doi-asserted-by":"crossref","first-page":"e1186","DOI":"10.1016\/S2214-109X(20)30286-2","article-title":"The global distribution of lymphatic filariasis, 2000\u20132018: a geospatial analysis","author":"Cromwell","year":"2020","journal-title":"Lancet Global Health"},{"issue":"8","key":"2021031805593034200_bib29","doi-asserted-by":"crossref","first-page":"e0008505","DOI":"10.1371\/journal.pntd.0008505","article-title":"The global progress of soil-transmitted helminthiases control in 2020 and World Health Organization targets for 2030","volume":"14","author":"Montresor","year":"2020","journal-title":"PLoS Neg Trop Dis"},{"key":"2021031805593034200_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"P\u00e9rez-Molina","year":"2018","journal-title":"Lancet"},{"key":"2021031805593034200_bib31","first-page":"33","volume-title":"Weekly Epidemiological Record (Chagas)","author":"World Health Organization","year":"2015"},{"key":"2021031805593034200_bib32","article-title":"Novatis Foundation joins new Global Partnership for Zero Leprosy","author":"Novartis","year":"2018"},{"key":"2021031805593034200_bib33","article-title":"Novartis renews drug donation of EgatenR (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke","author":"Novartis","year":"2018."}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/115\/2\/136\/36631978\/traa167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/115\/2\/136\/36631978\/traa167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T05:59:59Z","timestamp":1616047199000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/115\/2\/136\/6102565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,16]]},"published-print":{"date-parts":[[2021,1,28]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/traa167","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"value":"0035-9203","type":"print"},{"value":"1878-3503","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2021,1,16]]}}}